Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Financing Activities: 2012-2024

Historic Cash from Financing Activities for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$2.5 million.

  • Theravance Biopharma's Cash from Financing Activities fell 7.53% to -$400,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 93.52%. This contributed to the annual value of -$2.5 million for FY2024, which is 98.74% up from last year.
  • Latest data reveals that Theravance Biopharma reported Cash from Financing Activities of -$2.5 million as of FY2024, which was up 98.74% from -$198.9 million recorded in FY2023.
  • Theravance Biopharma's 5-year Cash from Financing Activities high stood at $279.9 million for FY2020, and its period low was -$758.8 million during FY2022.
  • For the 3-year period, Theravance Biopharma's Cash from Financing Activities averaged around -$320.1 million, with its median value being -$198.9 million (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 21,579.40% in 2020, then tumbled by 926.05% in 2022.
  • Over the past 5 years, Theravance Biopharma's Cash from Financing Activities (Yearly) stood at $279.9 million in 2020, then slumped by 67.18% to $91.9 million in 2021, then tumbled by 926.05% to -$758.8 million in 2022, then soared by 73.78% to -$198.9 million in 2023, then skyrocketed by 98.74% to -$2.5 million in 2024.